在Bamlanivimab治疗后长期COVID
Teresa H Evering1, Carlee B Moser2, Nikolaus Jilg3
1Department of Medicine, Weill Cornell Medicine, New York, New York.
长期的COVID影响了18%的门诊患者接受了巴姆拉尼维马布治疗,无论病毒载量如何. 治疗后的早期症状以及吸烟和女性性别等因素预测了长期的COVID发展.
科学领域:
- 传染性疾病 传染性疾病
- 免疫学 免疫学 免疫学
- 公共卫生 公共卫生
背景情况:
- 有限的前性数据存在于长期COVID在门诊患者治疗COVID-19.
- 这项研究评估了巴姆拉尼维玛布治疗后的长期COVID频率和预测因素.
研究的目的:
- 确定在接受Bamlanivimab治疗COVID-19的患者中长期COVID的发生率.
- 为了确定与长期COVID发展相关的预测因素.
主要方法:
- 分析了接受巴姆拉尼维玛的ACTIV-2/A5401试验参与者的数据.
- 长期COVID被定义为24周持续症状;用于关联分析的回归模型.
主要成果:
- 在506名参与者中,18%的人在24周后报告了长期COVID.
- 预测因素包括吸烟 (aRR 2.41),女性性别 (aRR 1.91),非西班牙裔种族 (aRR 1.92) 和早期症状 (aRR 2.70).
- 鼻腔SARS-CoV-2RNA水平与长期COVID没有关联.
结论:
- 长期COVID可以发生,尽管早期单克隆抗体治疗.
- 吸烟,女性性和治疗后早期症状是重要的预测因素.
- 早期干预可能至关重要,只要COVID过程似乎开始得很早.
更多相关视频
08:41Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
Published on: November 5, 2021
14:48Visualizing Lung Cellular Adaptations during Combined Ozone and LPS Induced Murine Acute Lung Injury
Published on: March 21, 2021
相关概念视频
Myocarditis III: Medical Management
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Pneumonia III: Complications and Assessment
Myocarditis IV: Nursing Management
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
